MedPath

Is it useful to continue administration of gonadotropin releasing hormone (GnRH) agonist after embryo transfer?

Completed
Conditions
Infertility treated by ICSI
Pregnancy and Childbirth
In vitro fertilization
Registration Number
ISRCTN13123887
Lead Sponsor
The Egyptian IVF Center (Egypt)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Female
Target Recruitment
446
Inclusion Criteria

Women under 40 years old undergoing intracytoplasmic sperm injection (ICSI) in the first or second trial and using the long GnRHa protocol

Exclusion Criteria

1. Donor eggs
2. Patients aged 40 or older
3. Pre-implantation Genetic Diagnosis (PGD) cycles
4. Patients with fibroids or congenital anomalies of the uterus

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Clinical pregnancy rate, which is measured by BhCG assay 2 weeks after embryo transfer followed by ultrasound at 6?7 weeks to detect fetal echoes and pulsation
Secondary Outcome Measures
NameTimeMethod
Ongoing pregnancy rate, which is diagnosed by ultrasound examination at 20?24 weeks pregnancy to document a viable pregnancy at this point
© Copyright 2025. All Rights Reserved by MedPath